DR HERZOG: What’s interesting is despite that agreement and despite guidelines that have come from SGO, ASCO and others, we still have a number of people — and we’ve seen this borne out in data presented at meetings this year, with as many as 20% to 40%, depending on which paper you read — are not getting tested in patients who have epithelial ovarian cancer, which is very unfortunate.

And I think some people, Neil, try to use a number of these red flags, so called, to try to determine. And they say, “Well, it wasn’t a high-grade serous cancer.” And we’re finding it’s really, by large part, other than mucinous tumors, agnostic to the histology. In other words, we’re finding a fair number of clear cells, certainly a high number of endometrioids, and so forth. So I think a lot of people try to start putting these filters in of — well, age is another issue. And they say, “Well” — but if you look at the age even, a significant number of women over 50 who have epithelial ovarian cancer harbor one of these BRCA mutations.

DR LOVE: And we actually just did, in the last 2 months, a survey of 230 patients. And amongst them were 78 patients who actually died in the last year of ovarian cancer. You took that survey. We gave it to you. And we found the exact same — we found 25% of those patients had never been BRCA-tested. This is a therapeutic issue here. This is a tumor marker, so —

DR HERZOG: That’s right.

DR LOVE: — it is kind of frustrating that the word’s not getting out there.

Treatment strategies in the management of ovarian cancer (OC)

Mechanism of action of PARP inhibitors and importance of BRCA testing

PARP inhibitors as primary treatment after multiple lines of therapy

PARP inhibitors as maintenance therapy

Tolerability of olaparib

Treatment options after olaparib failure

Differences among PARP inhibitors

Future directions in OC research